The team of Indonesian scientists conducting phase three clinical trials on a COVID-19 candidate vaccine developed by Chinese biopharmaceutical company Sinovac Biotech has said that the trials are still ongoing, despite the suspension of a similar trial in Brazil.

Brazil’s National Health Surveillance Agency reported a serious adverse event (SAE) on Oct. 29 in a study participant involved in the phase three trial of the Sinovac vaccine, leading to a decision to suspend the trial in the country. Pauses in clinical trials are common and were also seen previously in the phase three trials for AstraZeneca’s and Johnson & Johnson’s candidate vaccines.

In the latest development, Sinovac on Tuesday released a clarification of interruption in the phase three trial.